Royston, L.; Royston, E.; Masouridi-Levrat, S.; Vernaz, N.; Chalandon, Y.; Van Delden, C.; Neofytos, D.
Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. Vaccines 2021, 9, 372.
https://doi.org/10.3390/vaccines9040372
AMA Style
Royston L, Royston E, Masouridi-Levrat S, Vernaz N, Chalandon Y, Van Delden C, Neofytos D.
Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. Vaccines. 2021; 9(4):372.
https://doi.org/10.3390/vaccines9040372
Chicago/Turabian Style
Royston, Léna, Eva Royston, Stavroula Masouridi-Levrat, Nathalie Vernaz, Yves Chalandon, Christian Van Delden, and Dionysios Neofytos.
2021. "Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study" Vaccines 9, no. 4: 372.
https://doi.org/10.3390/vaccines9040372
APA Style
Royston, L., Royston, E., Masouridi-Levrat, S., Vernaz, N., Chalandon, Y., Van Delden, C., & Neofytos, D.
(2021). Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. Vaccines, 9(4), 372.
https://doi.org/10.3390/vaccines9040372